Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Get future ready with this LGPS governance roadmap
We don’t yet have the final requirements and nor do we know exactly when they will come into force, but there’s no doubt big change is coming and admi
What does stagflation mean for equity investors
Schroders, examines how concern is growing that an energy shock triggered by the Iran war will lead to a period of stagflation - something that may ma
Let AI do the ordinary so humans can do the extraordinary
See how early adopters are using AI to elevate human judgment and creativity. As AI adoption expands globally, board members and senior leaders are de

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.